Open label tissue plasminogen activator for stroke: The oregon experience

Robert Egan, Helmi Lutsep, Wayne Clark, Joseph Quinn, Kathy Kearns, Alexandre Lockfeld, Stephen Ireland, Steven Goins, Gary Buchholz

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Tissue plasminogen activator (t-PA) is the first effective treatment for stroke. This study sought to explore the outcome of patients treated with t-PA in the community after approval of its use in the treatment of stroke in June, 1996. Methods: All patients with acute stroke within the 6-hospital Oregon Stroke Center network were screened for potential t-PA treatment. Baseline and 24-hour outcome assessments were performed with the use of the National Institutes of Health Stroke Scale (NIHSS) and computed tomography (CT); 3-month outcome was evaluated by using the Modified Rankin scale. Results: Thirty-three patients who met the criteria for t-PA therapy were treated within 3 hours of symptom onset. All but 2 strokes were in the anterior circulation; 48.5% were cardioembolic. The NIHSS scores at 24 hours after administration of t-PA (mean, 14.7) showed modest gains from baseline NIHSS scores (mean, 16.6). Twelve patients (36%) had minimal or no deficits at 3 months. Three patients (9%), all of whom had baseline NIHSS scores of 20 or more, had symptomatic intracranial hemorrhages, 2 of which were fatal (6%). Conclusion: This study shows the feasibility of treating acute stroke with t-PA in the community. The percentage of fully recovered patients at 3 months mirrored those in the National Institute of Neurologic Disorders and Stroke (NINDS) trial.

Original languageEnglish (US)
Pages (from-to)287-290
Number of pages4
JournalJournal of Stroke and Cerebrovascular Diseases
Volume8
Issue number5
DOIs
StatePublished - Sep 1999

Fingerprint

Tissue Plasminogen Activator
Stroke
National Institutes of Health (U.S.)
Intracranial Hemorrhages
Feasibility Studies
Therapeutics
Nervous System Diseases
Tomography
Outcome Assessment (Health Care)

Keywords

  • Community
  • Infarction
  • Ischemia
  • t-Pa
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery
  • Rehabilitation
  • Cardiology and Cardiovascular Medicine

Cite this

Open label tissue plasminogen activator for stroke : The oregon experience. / Egan, Robert; Lutsep, Helmi; Clark, Wayne; Quinn, Joseph; Kearns, Kathy; Lockfeld, Alexandre; Ireland, Stephen; Goins, Steven; Buchholz, Gary.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 8, No. 5, 09.1999, p. 287-290.

Research output: Contribution to journalArticle

Egan, Robert ; Lutsep, Helmi ; Clark, Wayne ; Quinn, Joseph ; Kearns, Kathy ; Lockfeld, Alexandre ; Ireland, Stephen ; Goins, Steven ; Buchholz, Gary. / Open label tissue plasminogen activator for stroke : The oregon experience. In: Journal of Stroke and Cerebrovascular Diseases. 1999 ; Vol. 8, No. 5. pp. 287-290.
@article{d6af6b3655fa42bc96098a82d742619a,
title = "Open label tissue plasminogen activator for stroke: The oregon experience",
abstract = "Background: Tissue plasminogen activator (t-PA) is the first effective treatment for stroke. This study sought to explore the outcome of patients treated with t-PA in the community after approval of its use in the treatment of stroke in June, 1996. Methods: All patients with acute stroke within the 6-hospital Oregon Stroke Center network were screened for potential t-PA treatment. Baseline and 24-hour outcome assessments were performed with the use of the National Institutes of Health Stroke Scale (NIHSS) and computed tomography (CT); 3-month outcome was evaluated by using the Modified Rankin scale. Results: Thirty-three patients who met the criteria for t-PA therapy were treated within 3 hours of symptom onset. All but 2 strokes were in the anterior circulation; 48.5{\%} were cardioembolic. The NIHSS scores at 24 hours after administration of t-PA (mean, 14.7) showed modest gains from baseline NIHSS scores (mean, 16.6). Twelve patients (36{\%}) had minimal or no deficits at 3 months. Three patients (9{\%}), all of whom had baseline NIHSS scores of 20 or more, had symptomatic intracranial hemorrhages, 2 of which were fatal (6{\%}). Conclusion: This study shows the feasibility of treating acute stroke with t-PA in the community. The percentage of fully recovered patients at 3 months mirrored those in the National Institute of Neurologic Disorders and Stroke (NINDS) trial.",
keywords = "Community, Infarction, Ischemia, t-Pa, Treatment",
author = "Robert Egan and Helmi Lutsep and Wayne Clark and Joseph Quinn and Kathy Kearns and Alexandre Lockfeld and Stephen Ireland and Steven Goins and Gary Buchholz",
year = "1999",
month = "9",
doi = "10.1016/S1052-3057(99)80001-9",
language = "English (US)",
volume = "8",
pages = "287--290",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Open label tissue plasminogen activator for stroke

T2 - The oregon experience

AU - Egan, Robert

AU - Lutsep, Helmi

AU - Clark, Wayne

AU - Quinn, Joseph

AU - Kearns, Kathy

AU - Lockfeld, Alexandre

AU - Ireland, Stephen

AU - Goins, Steven

AU - Buchholz, Gary

PY - 1999/9

Y1 - 1999/9

N2 - Background: Tissue plasminogen activator (t-PA) is the first effective treatment for stroke. This study sought to explore the outcome of patients treated with t-PA in the community after approval of its use in the treatment of stroke in June, 1996. Methods: All patients with acute stroke within the 6-hospital Oregon Stroke Center network were screened for potential t-PA treatment. Baseline and 24-hour outcome assessments were performed with the use of the National Institutes of Health Stroke Scale (NIHSS) and computed tomography (CT); 3-month outcome was evaluated by using the Modified Rankin scale. Results: Thirty-three patients who met the criteria for t-PA therapy were treated within 3 hours of symptom onset. All but 2 strokes were in the anterior circulation; 48.5% were cardioembolic. The NIHSS scores at 24 hours after administration of t-PA (mean, 14.7) showed modest gains from baseline NIHSS scores (mean, 16.6). Twelve patients (36%) had minimal or no deficits at 3 months. Three patients (9%), all of whom had baseline NIHSS scores of 20 or more, had symptomatic intracranial hemorrhages, 2 of which were fatal (6%). Conclusion: This study shows the feasibility of treating acute stroke with t-PA in the community. The percentage of fully recovered patients at 3 months mirrored those in the National Institute of Neurologic Disorders and Stroke (NINDS) trial.

AB - Background: Tissue plasminogen activator (t-PA) is the first effective treatment for stroke. This study sought to explore the outcome of patients treated with t-PA in the community after approval of its use in the treatment of stroke in June, 1996. Methods: All patients with acute stroke within the 6-hospital Oregon Stroke Center network were screened for potential t-PA treatment. Baseline and 24-hour outcome assessments were performed with the use of the National Institutes of Health Stroke Scale (NIHSS) and computed tomography (CT); 3-month outcome was evaluated by using the Modified Rankin scale. Results: Thirty-three patients who met the criteria for t-PA therapy were treated within 3 hours of symptom onset. All but 2 strokes were in the anterior circulation; 48.5% were cardioembolic. The NIHSS scores at 24 hours after administration of t-PA (mean, 14.7) showed modest gains from baseline NIHSS scores (mean, 16.6). Twelve patients (36%) had minimal or no deficits at 3 months. Three patients (9%), all of whom had baseline NIHSS scores of 20 or more, had symptomatic intracranial hemorrhages, 2 of which were fatal (6%). Conclusion: This study shows the feasibility of treating acute stroke with t-PA in the community. The percentage of fully recovered patients at 3 months mirrored those in the National Institute of Neurologic Disorders and Stroke (NINDS) trial.

KW - Community

KW - Infarction

KW - Ischemia

KW - t-Pa

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0001393763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0001393763&partnerID=8YFLogxK

U2 - 10.1016/S1052-3057(99)80001-9

DO - 10.1016/S1052-3057(99)80001-9

M3 - Article

C2 - 17895176

AN - SCOPUS:0001393763

VL - 8

SP - 287

EP - 290

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 5

ER -